515PTepotinib + gefitinib (TEP+GEF) in MET+/epidermal growth factor receptor (EGFR)-mutant non-small lung cancer (NSCLC): Phase II data. (25th November 2018) - Wu, Y-L; Zhou, J; Lu, S; Zhang, Y; Zhao, J; Pan, H; Chen, Y-M; Chian, C-F; Bruns, R; Johne, A; Scheele, J; Cheng, Y